Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow M R, Lowes B D
Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA.
J Card Fail. 2000 Jun;6(2):115-9.
Beta-blockade consistently improves myocardial systolic function in patients with both nonischemic and ischemic cardiomyopathy. The effects of beta-blockade on Adriamycin-induced cardiomyopathy (ACM), however, are unknown. We retrospectively evaluated the effects of beta-blockade on patients with ACM by using a case-controlled design. The control group consisted of 16 consecutively chosen age- and sex-matched patients with idiopathic dilated cardiomyopathy (IDC) who were treated with beta-blockers. Patients with ACM had a baseline mean left ventricular ejection fraction (LVEF) of 28%, which improved to 41% (P = .041) after treatment with beta-blockers. The control group had a baseline mean LVEF of 26%, which improved to 32% (P = .015) after treatment. The mean duration of beta-blocker therapy in the Adriamycin and control groups was 8 and 9 months, respectively. The degree of improvement between the 2 groups was not significantly different. Beta-blockers have a beneficial effect on cardiac function in patients with ACM, which is at least comparable with other forms of heart failure with systolic dysfunction.
β受体阻滞剂持续改善非缺血性和缺血性心肌病患者的心肌收缩功能。然而，β受体阻滞剂对阿霉素诱导的心肌病（ACM）的影响尚不清楚。我们采用病例对照设计，回顾性评估了β受体阻滞剂对ACM患者的影响。对照组由16例连续入选的年龄和性别匹配的特发性扩张型心肌病（IDC）患者组成，他们接受了β受体阻滞剂治疗。ACM患者的基线平均左心室射血分数（LVEF）为28%，在用β受体阻滞剂治疗后提高到41%（P = 0.041）。对照组的基线平均LVEF为26%，治疗后提高到32%（P = 0.015）。阿霉素组和对照组β受体阻滞剂治疗的平均持续时间分别为8个月和9个月。两组之间的改善程度没有显著差异。β受体阻滞剂对ACM患者的心脏功能有有益作用，这至少与其他形式的收缩功能障碍性心力衰竭相当。
